Home > SANTE - SCIENCES DE LA VIE > Industrie Pharmaceutique > Alkermes Inc: Premium Company ...
AUTRES RESSOURCES
 
AUTRES SECTEURS
 
TOUS NOS SECTEURS
 
Industrie Pharmaceutique > Etude de marché sectorielle
 Alkermes Inc: Premium Company Profile
€ 396,00
Editeur :
Datamonitor
Langue :
Anglais
Date de publication :
Décembre 2007
Taille du document :
52
Autres informations :
Description , Table des matières
 

Recevez cette publication aujourd'hui !
Plus d'information ?
+33 437 37 1637
 
Documents Publics
1,200,000 documents
Téléchargement illimités
 
Etudes Privées
50,000 rapports et études
Paiement à la piéce
 
1.Télécharger nos rapports publics

Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...

Nos documents publics sur le même théme (5)
Biotechnologies and Genetics market in Canada
52 pages | Mars 2001 | Anglais
 
 
   
Main focus: biotechnology,bioinformatics,bio informatics,...,...
Research focus: market size and estimates,market segmentation,
Geographic focus: canada,united kingdom,usa,france
   
Agricultural chemicals market in USA
101 pages | Décembre 2005 | Anglais
 
 
   
Main focus: pesticides,biotechnology,biotech
Research focus: market definition,industry structure,
Geographic focus: usa,mexico,japan,canada,china,uruguay,india,...
   
Agricultural chemicals market in USA
92 pages | Octobre 2004 | Anglais
 
 
   
Main focus: pesticides,biopesticide,biotechnology,biotech
Research focus: market definition,market outlook,
Geographic focus: usa,japan,mexico,canada,croatia,france
   
Biotechnologies and Genetics market in Western Europe
271 pages | Juillet 2006 | Anglais
 
 
   
Main focus: biotechnology,biotech,biotech crops,bioinformatic,...,...
Research focus: competition analysis,market size and estimates,
Geographic focus: france,united kingdom,hungary,czech republic,...
   
Biotechnologies and Genetics market in USA
90 pages | Janvier 1998 | Anglais
 
 
   
Main focus: biotechnology,biotech,genetics,drug discovery,...
Research focus: competition analysis,market outlook,
Geographic focus: usa,india,uruguay,chile,colombia,venezuela,...
   
Autres recherches sur le même thème
Rechercher d'autres rapports publics à télécharger
 
 
 
2. Rechercher d'autres rapports et études à commander

Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux


Rapports privés en relation
The Drug Delivery Outlook to 2005
150 pages | Février 1999 |
Strategic overview : defines and values the market covered in the report, provides a macro analysis of the reasons why the drug delivery sector is growing at current rates and predicts how the c
795,00 €
 
 
Top Ten and Emerging Pharmaceutical markets
214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals.
Mar
795,00 €
 
 
Healthcare In Northern Ireland
52 pages | Mai 2000 |
The Northern Ireland Presentation Includes:- The Structure Of The Health Service In Northern Ireland- Total Expenditure On Health & Personal Social Services- Number Of Inpatient Beds, BY Area- Occ
327,00 €
 
 
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure
955,00 €
 
 
Maximising the Drug Lifecycle
102 pages | Août 2001 |
Up to $100bn of the 2000 pharmaceutical market, including blockbuster drugs with combined sales of $34bn will be exposed to generic competition by 2005.Maximising The Drug Lifecycle provides a detaile
955,00 €
 
 
The Pharmacogenomics Outlook
174 pages | Août 2000 |
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differenc
955,00 €
 
 
Lifestyle Drugs Outlook to 2005
130 pages | Février 1999 |
Definition of lifestyle drugs : The disease, product and social characteristics that make a drug lifestyle drug.
Epidemiology : The patient potential for lifestyle drugs such as sexual dysfuncti
795,00 €
 
 
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused
955,00 €
 
 
Pharmaceutical Pricing Strategies
121 pages | Juillet 1998 |
Which pricing strategies will enable your company to maximise profitability? As healthcare cost-containment intensifies and pricing freedom is eroded, the need to develop new strategies to mainta
795,00 €
 
 
The Pharmaceutical Industry Online
88 pages | Juillet 2002 |
In the United States, eMarketer projects that business-to-business e-commerce trade will grow to $1.3 trillion by 2005, while online trade in the health car
800,00 €
 
 
 
Autres secteurs en relation
Rechercher d'autres rapports!
 
 
 
Présentation de l'étude de marché - Description & Table des matières
 Alkermes Inc: Premium Company Profile

Introduction

Alkermes is a biotechnology company focused on drug development process from a patient-centric perspective, beginning with a thorough understanding of the challenges patients face on a day-to-day basis. The company's acquisition of Medisorb Technologies and Advanced Inhalation Research (AIR) in 1996 and 1996 have resulted Alkermes in emerging as strong player with proven proprietary technologies.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


  • Highlights

    Alkermes develops innovative medicines based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases and improve patient's lives.

    The company has two commercial products: Risperdal Consta (risperidone), a long-acting atypical antipsychotic medication for schizophrenia and Vivitrol (naltrexone for extended-release injectable suspension), the first and only once-monthly injectable medication for the treatment of alcohol dependence

    Its product candidates include ALKS 29 for alcohol dependence, AIR Inhaled Insulin (AIR Insulin) for diabetes, Exenatide LAR for Type 2 diabetes and AIR PTH for Osteoporosis. It enters into collaborations with pharmaceutical and biotechnology companies to develop new product candidates based on existing drugs incorporating its technologies.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization


  •  

    TABLE OF CONTENTS
    Overview 1
    Catalyst 1
    Summary 1
    Company Structure 6
    Company Overview and Key Facts 6
    Business Description 7
    History 8
    Locations and Subsidiaries 11
    Company Financials 12
    Stock Market Performance 12
    P&L 15
    Balance Sheet 18
    Cash Flow 18
    Business Segment Performance 19
    Products & Services 22
    Marketed Products 22
    Pipeline Products 23
    Technologies 25
    AC Forecast Product Sales 26
    Competitors and Strategic Business Relationships 27
    Key Competitors 27
    Key Suppliers 27
    Key Clients 28
    Shareholding Structure 29
    Strategy 30
    Company View 30
    Corporate Strategy 31
    SWOT Analysis 32
    Overview 32
    Strengths 33
    Weaknesses 34
    Opportunities 35
    Threats 36
    Value Chain Analysis 37
    Overview 37
    Product Development 38
    Manufacturing 39
    Scorecard 40
    Overview 40
    Scorecard Analysis 41
    Key Employees 42
    List of Key Employees 42
    Key Employee Biographies 43
    Financial and Operational Overview 49
    Financial and Operational Overview 49
    APPENDIX 52
    Ask the analyst 52
    Datamonitor consulting 52
    Disclaimer 52


    TABLE OF FIGURES
    Figure 1: Alkermes - Operating Revenue/Cost Analysis, 2002-2007 ($ Mn) 16
    Figure 2: Alkermes - Key Strategic Revenues, 2003-2007 ($ Mn) 21


    TABLE OF TABLES
    Table 1: Alkermes - Key Facts 6
    Table 2: Alkermes – Locations and Subsidiaries 11
    Table 3: Alkermes - Year-End Share Price and Market Capitalization, 2002-2006 ($) 12
    Table 4: Alkermes - Key Events Impacting Share Price Performance 13
    Table 5: Alkermes - Operating Revenue/Cost Analysis, 2002-2007 ($ Mn) 15
    Table 6: Alkermes - Operating Cost Ratio Analysis, 2002-2007 (% of total revenues) 17
    Table 7: Alkermes - Balance Sheet, 2002-2006 ($ Mn) 18
    Table 8: Alkermes – Cash Flow, 2002-2006 ($ Mn) 18
    Table 9: Alkermes - Revenue Breakdown by Division, 2002-2007 ($ Mn) 19
    Table 10: Alkermes - Marketed Products 22
    Table 11: Alkermes - In-house Pipeline Products 23
    Table 12: Alkermes - Collaboration Products 23
    Table 13: Alkermes - Forecast Sales, 2006-2011 ($ Mn) 26
    Table 14: Alkermes - Key Competitors 27
    Table 15: Alkermes - Key Suppliers 28
    Table 16: Alkermes - Key Clients 28
    Table 17: Alkermes - Key Shareholders 29
    Table 18: Alkermes - SWOT Analysis Summary 32
    Table 19: Alkermes - Value Chain Analysis 38
    Table 20: Alkermes - Scorecard 40
    Table 21: Alkermes - Key Employees 42
    Table 22: Alkermes - Financial and Operational Overview 50



    New Search:

    PPLSEN